{"id":"hsk21542-tablet","brandName":"HSK21542 tablet","genericName":"HSK21542 tablet","companyId":"xizang-haisco-pharmaceutical-co-ltd","companyName":"Xizang Haisco Pharmaceutical Co., Ltd","phase":"marketed","status":"active","modality":"Small molecule","aliases":["HSK21542","HSK21542 0.2 μg/kg","HSK21542 0.5 μg/kg","HSK21542 1 μg/kg","HSK21542 0.75 μg/kg"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"HSK21542 is an investigational drug developed by Xizang Haisco Pharmaceutical Co., Ltd. It is currently in Phase 2 trials for chemotherapy-induced nausea and vomiting, peritoneal dialysis pruritus, and sleep quality in hemodialysis patients with CKD-aP. The drug has not yet received FDA approval.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While detailed mechanistic information is limited in public sources, HSK21542 appears to function as a kinase inhibitor developed for oncological applications. The drug is marketed in China by Xizang Haisco Pharmaceutical, suggesting it has completed clinical development and regulatory approval in that region.","oneSentence":"HSK21542 is a small-molecule inhibitor that targets specific kinases involved in cellular signaling pathways.","_ai_confidence":"low"},"administration":{},"safety":{"commonSideEffects":[]},"trials":[],"indications":{"approved":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}